Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care.

Current Opinion in Cardiology
Subodh VermaMikhail N Kosiborod

Abstract

The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes. Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients.

References

Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Mar 10, 2012·European Journal of Heart Failure·Manuel Martínez-SellésUNKNOWN Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC)
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·John J V McMurrayMarc A Pfeffer
Dec 4, 2014·The Lancet. Diabetes & Endocrinology·Anoop Dinesh ShahHarry Hemingway
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Jun 14, 2017·The American Journal of Cardiology·Michael Lehrke, Nikolaus Marx
Jun 26, 2018·The Lancet. Diabetes & Endocrinology·Vlado PerkovicBruce Neal
Aug 23, 2018·Diabetologia·Subodh Verma, John J V McMurray
Nov 7, 2018·The Lancet. Diabetes & Endocrinology·Subodh VermaDeepak L Bhatt
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Nov 13, 2018·JAMA : the Journal of the American Medical Association·Julio RosenstockUNKNOWN CARMELINA Investigators
Nov 15, 2018·Lancet·Subodh VermaC David Mazer
Dec 6, 2018·Cell Metabolism·Kim A ConnellySubodh Verma
Mar 19, 2019·Circulation·Subodh Verma, John J V McMurray
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Jun 12, 2019·Circulation·Subodh Verma, Deepak L Bhatt
Jun 21, 2019·Current Opinion in Cardiology·Subodh VermaJaved Butler
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Sep 20, 2019·The New England Journal of Medicine·John J V McMurrayUNKNOWN DAPA-HF Trial Committees and Investigators
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Mar 12, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Erika OpingariRichard E Gilbert

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.